

10/550651

JG20 Rec'd PCT/PTC 26 SEP 2005

TMH:dv 09/23/05 424648 I-013-03
Attorney Reference Number 6395-67675-06

Express Mail Label No. EV514205630US
Date of Deposit: September 26, 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Lal and Owen

Application No. _____

Filed: Herewith

Confirmation No. _____

For: IMMUNOGENIC HIV-1 MULTI-CLADE,
MULTIVALENT CONSTRUCTS AND
METHODS OF THEIR USE

Examiner: _____

Art Unit: _____

Attorney Reference No. 6395-67675-06

MAIL STOP PCT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)(2)

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Copies of United States patents and United States published patent applications do not have to be provided to the Patent Office (37 C.F.R. 1.98(a)(2)(ii)). Copies of unpublished U.S. applications do not have to be provided, as long as the application is available on PAIR, as this requirement of 37 C.F.R. § 1.98(a)(2)(iii) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on October 19, 2004 (1287 OG 163). Applicants will provide copies of such patents or applications upon request.

Applicants filed this Information Disclosure Statement ("IDS") within three months of the date of entry of the national stage as set forth in § 1.491 in an international application. It is believed that no fee is due to file this IDS. If the Commissioner determines that a fee is due, Deposit Account authority is provided on the accompanying transmittal letter.

10/550651

JC20 Rec'd PGT/PTC 26 SEP 2005

TMH:dv 09/23/05 424648 I-013-03

Attorney Reference Number 6395-67675-06

Express Mail Label No. EV514205630US

Date of Deposit: September 26, 2005

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

Tanya M. Harding, Ph.D.
Registration No. 42,630

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket Number	6395-67675-06
	Application Number	10/550651
	Filing Date	Herewith
	First Named Inventor	Lal
	Art Unit	
	Examiner Name	

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		US 2002/0119127	August 29, 2002	Sette <i>et al.</i>
		US 2002/0182222	December 5, 2002	Groot
		US 2003/0108562	June 12, 2003	Hanke <i>et al.</i>
		5,633,234	May 27, 1997	August <i>et al.</i>
		6,319,503	November 20, 2001	Kenten <i>et al.</i>
		6,534,482	March 18, 2003	Fikes <i>et al.</i>

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		EP	1 130 289 A	5 Sept 2001	Bosch <i>et al.</i>
		PCT	WO 99/58658	18 Nov 1999	Fikes <i>et al.</i>
		PCT	WO 00/29008	25 May 2000	Jagannadha <i>et al.</i>
		PCT	WO 01/12216	22 Feb 2001	Kenten <i>et al.</i>
		PCT	WO 01/19408	22 Mar 2001	Hedley <i>et al.</i>
		PCT	WO 01/24810	12 Apr 2001	Sette <i>et al.</i>
		PCT	WO 02/080851	17 Oct 2002	August <i>et al.</i>

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Attorney Docket Number 6395-67675-06	
				Application Number 10/550651	
				Filing Date Herewith	
				First Named Inventor Lal	
				Art Unit	
				Examiner Name	
		PCT	WO 02/36806	10 May 2002	Pavlakakis <i>et al.</i>
		PCT	WO 2003/029285	10 Apr 2003	Cardinaud <i>et al.</i>
		PCT	WO 03/097675	27 Nov 2003	Howley <i>et al.</i>
Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS			
		Amara <i>et al.</i> , "Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA Vaccine," <i>Science</i> 292:69-74 (April 6, 2001)			
		Bonini <i>et al.</i> , "Targeting Antigen in Mature Dendritic Cells for Simultaneous Stimulation of CD4 ⁺ and CD8 ⁺ T Cells," <i>J. Immunology</i> 166:5250-5257 (2001)			
		Boyer <i>et al.</i> , "HIV-1 DNA based vaccine induces a CD8 mediated cross-clade CTL response," <i>Dev Biol Stand</i> 95:147-153 (1998) <i>Abstract Only</i>			
		Fredericksen <i>et al.</i> , "Inhibition of endosomal/lysosomal degradation increases the infectivity of human immunodeficiency virus," <i>J Virology</i> 72(22):11440-11446 (November 2002) <i>Abstract Only</i>			
		Fujita <i>et al.</i> , "In vitro binding study of adaptor protein complex (AP-1) to lysosomal targeting motif (LI-motif)," <i>Biochem Biophys Res Commun</i> 255(1):54-58 (February 1999) <i>Abstract Only</i>			
		Hanke and McMichael, "Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya," <i>Nature Medicine</i> 6(9):951-955 (September 2000)			
		Keating <i>et al.</i> , "Cross-clade T lymphocyte-mediated immunity to HIV type 1: implications for vaccine design and immunodetection assays," <i>AIDS Res Hum Retroviruses</i> 18(14):1067-1079 (September 20, 2002) <i>Abstract Only</i>			
		Kong Wing-Pui <i>et al.</i> , "Immunogenicity of Multiple gene and clade human immunodeficiency virus type 1 DNA vaccines," <i>J Virology</i> 77(23):12764-12772 (December 2003)			
		Lacaille <i>et al.</i> , "Targeting of HIV-1 Nef to the Centrosome: Implications for Antigen Processing," <i>Traffic</i> 1:884-891 (2000)			
		Lacasse <i>et al.</i> , "Fusion-competent vaccines: Broad neutralization of primary isolates of HIV," <i>Science</i> 283(5400):357-362 (January 15, 1999)			
		Livingston <i>et al.</i> , "Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines," <i>Vaccine</i> 19:4652-4660 (2001)			

EXAMINER SIGNATURE:	DATE CONSIDERED:
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Attorney Docket Number	6395-67675-06
		Application Number	10/550651
		Filing Date	Herewith
		First Named Inventor	Lal
		Art Unit	
		Examiner Name	
		Lohnas <i>et al.</i> , "Epitope-Specific Antibody and Suppression of Autoantibody Responses Against a Hybrid Self Protein," <i>J. Immunology</i> 161:6518-6525 (1998)	
		Lu, "HIV-1 Gag DNA Vaccine Chimera with Expression and Adjuvant Properties of the Lysosomal-Associated Membrane Protein (LAMP) and Dendritic Cell Multi-Lectin Receptor (DC-MLR) in an AAV-ITR Plasmid Vector," <i>Aids Vaccine Conference Abstract URL: http://63.84.172.40/Posters/312.1.pdf</i> (September 7, 2001)	
		Owen <i>et al.</i> , "Susceptibility of diverse primary HIV isolates with varying co-receptor specificity's to CXCR4 antagonistic compounds," <i>J Medical Virology</i> 68(2):147-155 (October 2002)	
		Ruff <i>et al.</i> , "The Enhanced Immune Response to the HIV gp160/LAMP Chimeric Gene Product Targeted to the Lysosome Membrane Protein Trafficking Pathway," <i>J. Biological Chemistry</i> 272(13):8671-8678 (1997)	
		Singh <i>et al.</i> , "Generation of genome-wide CD8 T cell responses in HLA-A*0201 transgenic mice by an HIV-1 ubiquitin expression library immunization vaccine," <i>J Immunology</i> 168(1):379-391 (January 1, 2002)	
		Suhriebier, "Multi-epitope DNA vaccines," <i>Immunol Cell Biol</i> 75(4):402-408 (1997) <i>Abstract Only</i>	
		Sykes and Johnston, "Genetic live vaccines mimic the antigenicity but not pathogenicity of live viruses," <i>DNA Cell Biol</i> 18(7):521-531 (July 1999)	
		Thomson <i>et al.</i> , "Delivery of Multiple CD8 Cytotoxic T Cell Epitopes by DNA Vaccination," <i>J Immunology</i> 160:1717-1723 (1998)	
		Thomson <i>et al.</i> , "Targeting a Polyepitope Protein Incorporating Multiple Class II-Restricted Viral Epitopes to the Secretory/Endocytic Pathway Facilitates Immune Recognition by CD4 ⁺ Cytotoxic T Lymphocytes: a Novel Approach to Vaccine Design," <i>J Virology</i> 72(3):2246-2252 (March 1998)	
		Tobery <i>et al.</i> , "Targeting of HIV-1 Antigens for Rapid Intracellular Degradation Enhances Cytotoxic T Lymphocyte (CTL) Recognition and the Induction of De Novo CTL Responses In Vivo After Immunization," <i>J Exp Med</i> 185(5):909-920 (March 3, 1997)	
		Tourdot <i>et al.</i> , "Design of a polyepitope construct for the induction of HLA-A0201-restricted HIV 1-specific CTL responses using HLA-A*0201 transgenic, H-2 class 1 KO mice," <i>Eur J Immunol</i> 31(10):3064-3074 (October 2001) <i>Abstract Only</i>	
		Rowell <i>et al.</i> , "Lysosome-Associated Membrane Protein-1-Mediated Targeting of the HIV-1 Envelope Protein to an Endosomal/Lysosomal Compartment Enhances its Presentation to MHC Class II-Restricted T Cells," <i>J Immunology</i> 155:1818-1828 (1995)	

EXAMINER SIGNATURE:	DATE CONSIDERED:
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

TMH:dv 09/23/05 424621 1-013-03
 Attorney Reference Number 6395-67675-06

Express Mail Label No. EV514205630US
 Date of Deposit: September 26, 2005

INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Attorney Docket Number	6395-67675-06
			Application Number	10/550651
			Filing Date	Herewith
			First Named Inventor	Lal
			Art Unit	
			Examiner Name	
		Woodberry <i>et al.</i> , "Immunogenicity of a Human Immunodeficiency Virus (HIV) Polytope Vaccine Containing Multiple HLA A2 HIV CD8 ⁺ Cytotoxic T-Cell Epitopes," <i>J Virology</i> 73(7):5320-5325 (July 1999)		

EXAMINER SIGNATURE:	DATE CONSIDERED:
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	